1. Executive Summary
2. Research Methodology
3. Migraine
3.1 Overview
3.1.1 Types of Migraine
3.1.2 Stages of Migraine
3.1.3 Symptoms of Migraine
3.1.4 Diagnosis
3.2 Treatment
3.2.1 Abortive Medications
3.2.2 Preventive Medications
3.2.3 Alternative Medicine
4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Treatment Drugs
4.2.2 Market Share by Nations
5. Market Segmentation by Drug Class
5.1 Triptan
5.1.1 Overview
5.1.2 Market Sizing (Actual & Forecasted)
5.2 CGRP
5.2.1 Overview
5.2.2 Market Sizing (Actual & Forecasted)
5.3 Others
5.3.1 Overview
5.3.2 Market Sizing (Actual & Forecasted)
6. Migraine Market Regional Analysis
6.1 North America
6.1.1 The US
6.2 Europe
6.2.1 France
6.2.2 Germany
6.2.3 Italy
6.2.4 Spain
6.2.5 The UK
6.3 Asia Pacific
6.3.1 Japan
7. Market Dynamics
7.1 Industry Trends & Development
7.1.1 Anti-CGRP Drugs Pipeline
7.1.2 Neuromodulation Devices for Migraine Treatment
7.1.3 Advent of Migraine Preventive Drug
7.1.5 Availability of Less Expensive Drugs
7.2 Growth Drivers
7.2.1 Increasing Incidence of Migraine Cases
7.2.2 Rising Female Population
7.2.3 Patent Expirations
7.3 Challenges
7.3.1 Poor Efficacy of Drugs
7.3.2 Regulatory Hurdle
7.3.3 Low Diagnosis Rate
8. Competitive Landscape
9. Company Profile
9.1 Eli Lilly & Company
9.2 Teva Pharmaceutical Industries
9.3 Alder Biopharmaceuticals
9.4 Amgen Inc.